Patent: 10,144,776

Summary for Patent: 10,144,776

Title:	Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
Abstract:	The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer\'s disease are provided.
Inventor(s):	Frey; William H. (White Bear Lake, MN), Hanson; Leah Ranae Bresin (Vadnais Heights, MN), Pokropinski; Sharon (Schaumburg, IL), Rausa; Francisco M. (Vernon Hills, IL)
Assignee:	Baxalta Incorporated (Bannockburn, IL) Baxalta GmbH (Zug, CH)
Application Number:	15/335,027
Patent Claims:	see list of patent claims

Details for Patent 10,144,776

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000		2033-02-26
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007		2033-02-26
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009		2033-02-26
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	02/07/2013		2033-02-26
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	09/17/2009		2033-02-26
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	02/06/2017		2033-02-26